Over-expression of cathepsin B in hepatocellular carcinomas predicts poor prognosis of HCC patients by Jian Ruan et al.
RESEARCH Open Access
Over-expression of cathepsin B in
hepatocellular carcinomas predicts
poor prognosis of HCC patients
Jian Ruan1*†, Haiyan Zheng2†, Xiaodong Rong3, Xiaomin Rong4, Junyi Zhang1, Weijia Fang5, Peng Zhao5
and Rongcheng Luo1
Abstract
Background: Several studies have found that Cathepsin B (CTSB) is up-regulated in many tumor types and
facilitates tumor progression. However, the role of CTSB in hepatocellular carcinoma (HCC) progression remains
unclear. This study was aimed at investigating the expression and role of CTSB in HCC in a large set of samples
and cell lines (MHCC-97H and MHCC-97 L), and evaluating the clinical and prognostic significance of CTSB
protein in patients with HCC.
Methods: The expression of CTSB was examined in HCC tissue and cell lines by Western-blotting, Real-time
PCR, and immunohistochemical staining. Wound healing assay and invasion assay were used to verify the
effect of CTSB on the migration and invasion ability of HCC cell lines. Tumor formation assay in nude mice
was used to analyze the effect of CTSB on the tumorigenicity of HCC cell lines.
Results: The status of CTSB protein in carcinoma tissues is much higher than that in paracarcinoma tissues.
The overall survival of the patients with high CTSB expression was significantly shorter than the low CTSB
expression group. High CTSB expression was significantly correlated with advanced clinical staging, histological
grade, and tumor recurrence. In vitro and in vivo experiments demonstrated that over-expression of CTSB in
MHCC-97 L cells promoted cell invasion and tumor progression ability. Down-regulation of CTSB in MHCC-97H
showed the opposite effects. These phenotypic changes caused by CTSB knockdown or over-expression correlated
with expression of the matrix metallopeptidase MMP-9. Moreover, multivariate analysis suggested that CTSB expression
might be an independent prognostic indicator for the survival of HCC patients after curative surgery.
Conclusions: CTSB might be involved in the development and progression of HCC as an oncogene, and thereby may
be a valuable prognostic marker for HCC patients.
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Background
Hepatocellular carcinoma (HCC) grows rapidly and
frequently associates with vascular invasion, metastasis,
recurrence, and poor prognosis. HCC is the fifth most
common human cancer and the third leading cause of
cancer death worldwide [1, 2]. The increase in world-
wide incidence and the high mortality of HCC highlight
the importance of understanding the molecular mecha-
nisms that trigger the neoplastic transformation of hepa-
tocytes and the progression of HCC. However, the
molecular mechanisms responsible for HCC develop-
ment have not been well defined.
Proteases perform essential functions in such pro-
cesses as ovulation [3], fertilization [4], bone remodeling
[5], cell migration [6, 7], inflammation [8, 9], angiogen-
esis [10, 11], and apoptosis [12, 13]. CTSB, composed of
a heavy chain of 25–26 kDa and a light chain of 5 kDa,
belongs to a family of lysosomal cysteine proteases and
plays an important role in intracellular proteolysis [14].
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Numerous studies have shown that overexpression of
CTSB is correlated with invasive and metastatic cancers.
CTSB is known to interact with cystatins and annexin II
tetramer (p11), which is also known as S100A10 [15].
These interactions place CTSB at crucial positions for
the proteolytic activation of extracellular matrix (ECM)
components, thereby enabling ECM degradation. It has
been observed that the promoter of CTSB contains a
GC-rich region including many SP1 sites, similar to a
housekeeping gene [16]. These SP1 sites are known to
increase in tumor cells [17]. Interestingly, it has been
observed that CTSB is also involved in autophagy and
cannibalism, as researchers have shown that tumor can-
nibalism is advantageous in tumor malignancy and is
possibly involved in specific immune resistance, enabling
tumor cells to recycle nutrients and maintain a prolifera-
tive and infiltrative phenotype [18]. This could also
explain why the cores of highly infiltrative tumors are
necrotic.
However, no research on CTSB has been done in HCC
so far. To explore the exact role of CTSB in HCC, we
investigated whether the expression of CTSB protein is
different between tumor tissues and normal tissues,
whether CTSB plays an important role in the develop-
ment and progression of HCC, and whether CTSB is a




Fresh tumor tissue samples with paired non-cancerous
liver tissue samples of 24 HCC patients were obtained in
operation from the Nanfang hospital and Cancer Center
of Southern medical university (SMUCC). A total of 168
paraffin-embedded HCC samples, which were histologi-
cally and clinically diagnosed in patients with radical
surgery in NanFang hospital, between 2000 and 2007,
were also included in this study. Resected specimens,
fixed in 10 % formalin solution and then embedded in
paraffin, were longitudinally sliced into 4-mm-thick sec-
tions. Representative sections were prepared and stained
with hematoxylin and eosin for histologic examination.
Western-blot was used to confirm the specificity of
CTSB staining in fresh HCC tissues with paired non-
cancerous liver tissues and cell lines MHCC-97H and
MHCC-97 L. None of these patients had received radio-
therapy or chemotherapy prior to surgical treatment.
Clinical and pathological data of the 168 patients with
HCC were collected, such as age, tumor size, stage,
differentiation grade, and recurrence. The tumor
stages were classified according to the 2010 TNM sta-
ging system of Union for International Cancer Con-
trol (UICC). Tumor differentiation was classified
using the Edmondson grading system. Clinical follow-
up information was obtained by telephone or from
the outpatient records.
Written Ethics Approval and Patient Consent from the
Research Ethics Committee of Nanfang Hospital and
SMUCC were obtained. Participants were recruited and
human experimentation was conducted in Nanfang Hos-
pital and SMUCC. We have obtained written informed
consent from all participants involved in the study.
Cell culture
The HCC cell lines MHCC-97H, MHCC-97 L, Huh-7,
HepG2, SMMC-7721, Bel-7404, and human hepatocyte
cell line HL-7702 were obtained from The Cell Bank of
Type Culture Collection of Chinese Academy of Sci-
ences. MHCC-97H and MHCC-97 L were derived from
the same parent cell MHCC-97 to ensure a similar gen-
etic background and yet dramatic differences in spontan-
eous metastatic behavior. Compared with MHCC-97 L,
which was not metastatic via subcutaneous inoculation,
MHCC-97H featured more overt multidirectional me-
tastasis. Cells were maintained in RPMI 1640 medium
(Gibco, Invitrogen, Carlsbad, CA, USA) supplemented
with 10 % fetal bovine serum (FBS; Hyclone, Logan, UT,
USA), penicillin (100 units/ml), and streptomycin (100
units/ml) at 37 °C in humidified 5 % CO2 incubator.
Western blot analysis
Equal amounts of protein lysates were separated by
SDS-PAGE and transferred onto nitrocellulose mem-
branes. Filters were probed with the following specific
primary antibodies: anti-CTSB (Cell signaling, Danvers,
MA, USA), MMP-9 (Abcam, Cambridge, MA, USA), β-
actin (Sigma, St Louis, MO, USA), PI3K and
phosphorylated-PI3K (Cell signaling, Danvers, MA,
USA), Akt and phosphorylated-Akt (Cell signaling, Dan-
vers, MA, USA), mTOR, and phosphorylated-mTOR
(Cell signaling, Danvers, MA, USA). Blots were then
incubated with horseradish peroxidase-conjugated sec-
ondary antibody (Pierce, Rockford, IL, USA) and visual-
ized by chemiluminescence. The band density was
quantified by densitometry using Scion Image software,
and normalized to β-actin levels.
Real-time RT-PCR analysis
Total RNA from human tissues was extracted using
Trizol reagent (Invitrogen, Carlsbad, CA, USA) accord-
ing to the manufacturer’s instructions. cDNA was syn-
thesized from 1 μg of total RNA by use of the
SuperScript® III First-Strand Synthesis System (Invitro-
gen, Carlsbad, CA). Real-time PCR was carried out using
CFX96 Real-Time System (BIO-RAD). SYBR green 2×
master mixture (Invitrogen, Carlsbad, CA, USA) was used
in a total volume of 10 μL. The primer sequences were as
follows: CTSB sense 5′- GGCCTCTATGACTCGCATGT
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-3′, antisense 5′- TTTGTAGGACGGGGTGTAGC -3′,
GAPDH sense 5′-TGTTGCCATCAATGACCCCTT-3′,
antisense 5′-CTCCACGACGTACTCAGCG-3′. GAPDH
was used as an internal control. All reactions were run in
triplicate in three independent experiments.
Immunohistochemical analysis
Immunohistochemical (IHC) staining was performed
using Dako Envision system (Dako, Carpinteria, CA) ac-
cording to the manufacturer’s instructions. Briefly, 4 μm
formalin-fixed paraffin-embedded sections were made
and subsequently deparaffinized with xylenes, and rehy-
drated through graded ethanol series to distilled water.
Antigen retrieval was done by heating sections with
EDTA antigenic retrieval buffer (pH 8.0) in a microwave
oven. Following endogenous peroxidase blocking in
0.3 % H2O2 for 15 minutes and nonspecific binding
blocking with normal goat serum for 30 minutes, the
sections were incubated with rabbit polyclonal anti-
CTSB antibody (1:50; Santa Cruz Biotechnology) over-
night at 4 °C. After sequential incubation with biotinylated
anti-goat secondary antibody (Zymed) and streptavidin-
horse-radish peroxidase (Zymed), reaction product was
developed with Diaminobenzidine (DAB). Negative con-
trol was composed of mixture with no primary antibody
but normal goat serum instead.
Three pathologists scored the immunohistochemically
stained slides independently. Sum of intensity and extent
score scaling from 0 to 7 was used as to assess and grade
expression of CTSB into two groups: low (<3) and high
(>3) expression.
Vector construction and transfection
The pcDNA3.0 vector was used to generate pcDNA-
CTSB. The CTSB shRNA Plasmid was purchased from
Santa Cruz Biotechnology (Cat. no: sc-29238-SH). Vec-
tor transfection was performed according to the instruc-
tions. MHCC-97 L cell line was transfected with pcDNA
expressing CTSB or empty vector, and MHCC-97H was
used to knock-down the expression of CTSB. MHCC-
97 L cells expressing CTSB or empty vector were
selected for 14 days with G418 after infection. MHCC-
97H cells transfected with CTSB-shRNA or Con-shRNA
were selected for 14 days with puromycin after infection.
In addition, MHCC-97H/CTSB-shRNA was transfected
with pcDNA expressing MMP-9, and then used for the
further experiments.
Wound Healing Assay
Cell migration ability was assessed by measuring the
movement of cells into scraped cellular area created by a
10 μl pipette tube when cells were grown to 80-90 %
confluence in six-well culture plates. The phase contrast
images of the wounds were recorded of 0, 24, 48 h and
three separate experiments were performed. Cells trans-
fected with empty vector and parental cells served as
controls.
Cell Invasion Assay
Upper chambers of 24-well transwell plate (Corning In-
corporated, New York, NY, USA) were coated with 50 %
Matrigel (BD Biosciences, Franklin, New Jersey, USA) in
phosphate-buffered saline. Cells were incubated in the
upper chamber. After 24 h incubation, invaded cells
were stained with 0.5 % crystal violet, examined by
bright field microscopy (OLYMPUS cx31, TOKYO,
Japan), and photographed. Invasion rate was quantified
by counting the invaded cells in five random fields per
chamber under the fluorescence microscope (OLYMPUS
IX71, TOKYO, Japan). Data summarized three inde-
pendent experiments.
Tumor formation in an animal model
Equivalent amounts of MHCC97L/CTSB cells and
MHCC97H/CTSB-shRNA cells (5 × 105 cells) were
injected subcutaneously into the right flank of female
BALB/c nude mice (Shanghai Slac Laboratory Animal
Co. Ltd, Shanghai, China) at 5 weeks of age (15–17.5 g)
respectively. Tumorigenesis procedure was observed by
measuring solid tumors in 3 dimensions with a caliper
for 21 days. Animals were sacrificed 21 days after injec-
tion. The experiments on mice had been approved by
the ethics committee at SMUCC.
Statistical analysis
Statistical analyses were performed using a statistical
software package (SPSS19.0, Chicago, IL). The signifi-
cance of CTSB mRNA levels was determined by t-
test. The chi-square test was used to analyze the
relationship between CTSB expression and clinico-
pathological characteristics. Survival times were evalu-
ated using the Kaplan and Meier survival curves, and
compared by the log-rank test. The significance of
various variables for survival was analyzed by multi-
variate survival analysis using Cox’s regression model.
P-value less than or equal to 5 percent was consid-
ered to be statistically significant.
Results
The Expression of CTSB in HCC Tissues and cell lines
To determine the expression of CTSB protein in HCC
tissues, Western blotting was performed in 24 HCC tis-
sues with paired non-cancerous tissues. Among 22 of 24
HCC tissues with paired normal tissues, clearly in-
creased levels of CTSB expression were detected in all
the tumors tissues in comparison to the paired non-
cancerous tissues (Fig. 1a and b). However, the level of
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Fig. 2 Analysis of CTSB protein in tissues by immunohistochemistry. CTSB expression was significantly increased in HCC tissues, when compared
with normal liver tissues, P < 0.001
Fig. 1 Expression levels of CTSB in HCC tissues as well as HCC cell lines. a Expression levels of CTSB protein in 24 paired HCC tissues by Western
blotting. N, paracarcinoma (normal) liver tissues. T, HCC tissues. b Quantitative analysis of CTSB protein in 24 paired HCC tissues. c. Western blot
analysis of CTSB protein expression in one hepatocyte cell line (HL-7702) and two HCC cell lines (MHCC-97 L and MHCC-97H)
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CTSB expression was higher in non-cancerous tissues
than that in tumors tissues in the rest of 2 paired of
HCC tissues (Fig. 1a, patient samples No. 7 and No. 15).
In addition, we first examined the expression of CTSB in
HL-7702, MHCC-97 L, and MHCC-97H to investigate
whether there was any correlation between CTSB
expression and the metastasis potential in HCC. As
presented in Fig. 1c, the level of CTSB protein in
MHCC-97H was much higher than that in MHCC-97 L
and HL-7702. No statistically significant difference was
found between MHCC-97 L and HL-7702. The RT-PCR
analysis had a result similar to that of Western blot
(data not shown). As expected, the highly metastatic
cell line (MHCC-97H) exhibited stronger signals of
CTSB than the lowly metastatic cell line (MHCC-
97 L). In HL-7702cells, CTSB was almost undetect-
able. These data suggested that CTSB might serve as
an oncogene in HCC.
To verify this observation, we further examined the
expression of CTSB protein in 168 paraffin-embedded
HCC samples and 37 normal liver (non-cancerous)
samples by immunohistochemical analysis. As shown
by immunohistochemical analysis, 78 of 168 (46.5 %)
paraffin-embedded HCC tissues showed weak or
negative staining of CTSB protein, while 50 of 168
(29.8 %) HCC tissues showed mainly moderate CTSB
staining (in the membrane and cytoplasm of cancer
cell), and 40 of 168 (23.7 %) showed strong staining
in tumor cells. 31 of the 37 non-cancerous tissues indi-
cated negative staining of CTSB and the rest of six non-
cancerous tissues showed weak expression (Fig. 2).
Additionally, the incidence of CTSB protein expres-
sion in well-differentiated carcinoma was significantly
lower than that in poorly differentiated tumors, and
CTSB expression was significantly related with tumor
differentiation (P = 0.003) (Table 1).
Correlation of CTSB expression with clinicopathological
features and Outcomes
The association between CTSB expression and the clini-
copathological outcomes is shown in Table 1. CTSB
expression was significantly correlated with stage, recur-
rence, and tumor differentiation. There was no signifi-
cant correlation between CTSB expression and age,
Table 1 Relationship between CTSB expression and
clinicopathologic features of HCC patients
Clinicopathologic
parameters
n CTSB expression P value
Positive (%) Negative (%)
All cases 168 90 (53.5 %) 78 (46.5 %)
Gender 0.562
Male 110 57 (51.8 %) 53 (48.2 %)
Female 58 32 (55.2 %) 26 (44.8 %)
Age (years) 0.310
<50 123 61 (49.6 %) 62 (50.4 %)
≥50 45 26 (57.8 %) 19 (42.2 %)
Tumor size (cm)a 0.622
<5 131 71 (54.2 %) 60 (45.8 %)
≥5 37 19 (51.4 %) 18 (48.6 %)
Serum HBsAg 0.125
Positive 147 82 (55.8 %) 65 (44.2 %)
Negative 21 10 (47.6 %) 11 (52.4 %)
Serum AFP (ng/ml) 0.814
<25 50 25 (50.0 %) 25 (50.0 %)
≥25 118 60 (50.8 %) 58 (49.2 %)
Cirrhosis 0.078
Presence 145 78 (53.8 %) 67 (46.2 %)
Absence 23 10 (43.5 %) 13 (56.5 %)
UICC stage 0.004
I + II 100 32 (32.0 %) 68 (68.0 %)
III + IV 68 48 (70.6 %) 20 (29.4 %)
Metastasis/Recurrence 0.000
Yes 133 88 (66.2 %) 45 (33.8 %)
No 35 12 (34.3 %) 23 (65.7 %)
Edmondson grade 0.003
Low (I/II) 82 32 (39.0 %) 50 (61.0 %)
High (III/IV) 86 56 (65.1 %) 30 (34.9 %)
a:The largest dimension of the tumor specimen
Fig. 3 Survival curves for patients with high CTSB expression versus
low CTSB-expressing carcinoma. The 5-year overall survival rate was
19.3 % in the high CTSB protein expression group (green line), but it
was 43.4 % in the low expression group (blue line), P = 0.032
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gender, tumor size, serum HBsAg, serum AFP, or liver
cirrhosis (Table 1).
Correlation of CTSB expression with overall survival
The median follow-up time for overall survival was
72 months for all patients. The 2-year and 5-year overall
rates for all patients were 53.4 % and 29.7 %, respectively.
Among these patients, the overall survival of the patients
with low CTSB expression (5-year overall rate, 43.4 %)
was significantly higher than the high CTSB expression
group (5-year overall rate, 19.3 %) (P =0.001, Fig. 3). Be-
sides CTSB expression level, tumor size, serum AFP, liver
cirrhosis, stage, tumor recurrence, and tumor differenti-
ation were also significantly correlated with overall sur-
vival in univariate analysis (Table 2). Furthermore, overall
survival was possibly correlated with age (P =0.053).
The Cox proportional hazards mode was employed to
evaluate the effects of the independent factors on overall
survival. These factors include CTSB expression, gender,
age, tumor size, Serum HBsAg, serum AFP, tumor size,
liver cirrhosis, stage, tumor recurrence, and tumor differ-
entiation. The results showed that CTSB expression,
serum AFP, tumor size, tumor recurrence and stage were
recognized as independent prognostic factors of survival
(Table 3). Therefore, Multivariate analysis indicated that
CTSB protein expression has a significant correlation with
poor prognosis of HCC patients as an independent factor.
Alteration of CTSB expression regulated migration and
invasion capabilities of HCC cells In Vitro
We successfully constructed stable clones over-
expressing CTSB from MHCC-97 L cells (Fig. 4a and b).
We employed wound healing assay to detect the effect
of CTSB on cell migration. As shown in Fig. 5a, an evi-
dent acceleration in the wound closure rate was ob-
served in MHCC-97 L/CTSB cells at 48 h compared
with the controls (P < 0.05). In the transwell assay
(Fig. 5c), the number of cells that passed through Matri-
gel in MHCC-97 L/CTSB group was higher than that in
the control groups (P < 0.05). As expected, overexpres-
sion of CTSB was accompanied by the enhanced inva-
siveness of MHCC-97 L cells.
The endogenous CTSB level in MHCC-97H was stably
knocked down by transfecting small interfering RNA
(Fig. 4c and d). Contrary to the effect of overexpression of
CTSB, down-regulation of endogenous CTSB in MHCC-
97H cells suppressed the migration and invasion abilities
compared with their controls (Fig. 5b and d).
Protein level of CTSB of four HCC cell lines was shown
in Additional file 1: Figure S1A. Huh-7 and Bel-7404
expressed the lowest and highest levels of CTSB among
four HCC cell lines respectively. Thus, huh-7 cells were
transfected with pcDNA expressing CTSB, and Bel-7404
cells were used to knock down CTSB expression. We
successfully established stable Huh-7 clones over-
expressing CTSB (Additional file 1: Figure S1B). In the
transwell assay (Additional file 1: Figure S1C), Huh-7/
CTSB displayed remarkable enhanced invasive ability as
compared with either Huh-7/Con or Huh-7. In addition,
Bel-7404 cells transfected with CTSB-shRNA had signifi-
cantly reduced level of CTSB protein than with Con-
shRNA, respectively (Additional file 1: Figure S1D). We
also employed transwell assay to explore the effect of
CTSB on cell invasion. As shown in Additional file 1: Fig-
ure S1E, Bel-7404/CTSB-shRNA showed much weaker in-
vasive activity than either Bel-7404 or Bel-7404/Con-
shRNA.
Table 2 Univariate survival analysis of 168 patients with HCC
Variable n Overall survival P value
2-year 5-year
CTSB expression 0.001
Positive 90 42.5 % 19.3 %
Negative 78 62.8 % 43.4 %
Gender 0.518
Male 110 57.9 % 33.4 %
Female 58 60.3 % 39.6 %
Age (years) 0.053
<50 123 61.2 % 40.9 %
≥50 45 54.1 % 35.4 %
Tumor size (cm)a 0.001
<5 131 68.2 % 47.6 %
≥5 37 49.8 % 27.2 %
Serum HBsAg 0.088
Positive 147 54.3 % 36.4 %
Negative 21 62.3 % 43.1 %
Serum AFP (ng/ml) 0.001
<25 50 70.3 % 51.3 %
≥25 118 52.6 % 33.3 %
Cirrhosis 0.031
Presence 145 52.9 % 23.3 %
Absence 23 63.7 % 43.6 %
UICC stage 0.001
I + II 100 75.2 % 49.8 %
III + IV 68 50.1 % 24.5 %
Metastasis/Recurrence 0.000
Yes 133 43.4 % 23.3 %
No 35 67.2 % 40.7 %
Edmondson grade 0.005
Low (I/II) 82 66.9 % 42.8 %
High (III/IV) 86 48.3 % 27.1 %
a:The largest dimension of the tumor specimen
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CTSB might regulate MMP-9 through PI3K/Akt signaling
pathway
MMP-9 has been implicated in HCC invasion and me-
tastasis, and up-regulation of MMP-9 can be achieved
by activation of PI3K/Akt pathways [19]. Western blot
analysis showed that the expression of p-Akt was signifi-
cantly increased in CTSB-overexpressing cells (Fig. 6a),
indicating that up-regulation of CTSB is able to enhance
Akt signaling, which in turn leads to concomitant up-
regulation of MMP-9 expression. In addition, inhibition of
Table 3 Cox regression analysis of patients with HCC
Variables Univariate P value
HR CI (95 %)
CTSB expression (1 = down,2 = over) 5.132 3.125 ~ 6.037 0.000
Gender (1 = male,2 = female) 0.511 0.327 ~ 1.078 0.106
Age (1 < 50,2 ≥ 50) 0.468 0.279 ~ 0.998 0.412
Serum HBsAg (1 = negative,2 = positive) 1.033 0.723 ~ 2.411 0.107
Serum AFP (1 < 25 ng/ml,2≥ 25 ng/ml) 3.415 2.379 ~ 4.866 0.009
Tumor size (1 < 5 cm,2 ≥ 5 cm) 1.756 1.218 ~ 3.321 0.039
Cirrhosis (1 = Absence,2 = Presence) 0.932 0.782 ~ 1.687 0.443
Metastasis/Recurrence (1 = no,2 = yes) 5.002 3.437 ~ 7.312 0.000
UICC stage (1 = I + II,2 = III + IV) 1.958 1.021 ~ 4.190 0.042
Edmondson grade (1 = High (III/IV),2 = Low (I/II)) 1.412 0.783 ~ 2.224 0.098
Fig. 4 CTSB expression in MHCC-97 L and MHCC-97H. a CTSB Protein of MHCC-97 L cells stably transfected with pcDNA-CTSB increased most
significant compared to MHCC-97 L/Con cells and MHCC-97 L cells. As detected by Western blotting. b MHCC-97 L/CTSB also show the highest
CTSB mRNA among the three. As detected by RT-PCR. c CTSB specific shRNA resulted in the reduction of CTSB protein in MHCC-97H cells.
d MHCC-97H/CTSB-shRNA show the lowest CTSB mRNA among the three. The expression of β-actin mRNA and protein was also examined and
served as control for sample loading. (**P < 0.01 as compared to parental groups, *P < 0.05 as compared to parental groups)
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CTSB resulted in significant diminishments of p-Akt and
MMP-9 expression in MHCC-97H cells (Fig. 6b). Further-
more, upregulation of MMP-9 partially rescued the ability
of CTSB knockdown cells to invade the Matrigel-
coatedmembrane (Fig. 6c and d), indicating that CTSB is
a major mediator of MMP-9 induction. This notion was
further supported by the results that MMP-9 expression
was decreased but CTSB expression was unchanged in
MHCC97L/CTSB cells after treatment with the PI3K/Akt
inhibitorLY294002 (Fig. 6e), which led to decreased inva-
sive ability of CTSB-overexpressing cells (Fig. 6f).
In addition, as shown in Additional file 2: Figure S2,
Western blot was applied to detect the expression of
components of PI3K transduction in HCC cell lines.
Protein levels of p-PI3K, p-Akt, and p-mTOR in
MHCC-97H/CTSB-shRNA were lower than both con-
trol groups (MHCC-97H and MHCC-97H/Con-shRNA),
while in MHCC-97 L/CTSB were higher than both
control groups (MHCC-97 L and MHCC-97 L/Con).
The findings above suggested that the effects of CTSB in
HCC cells are partially mediated by PI3K/Akt signaling.
CTSB enhanced Tumorigenicity in vivo
To further investigate the role of CTSB in HCC progres-
sion, we assessed the effect of CTSB up-regulation on
the growth of HCC xenograft tumors in nude mice
injected with CTSB-overexpressing cells or control cells.
MHCC-97 L/CTSB tumors grew much faster than con-
trol tumors (Fig. 7a). At the end of the study day 21,
tumor weight of the control group (1.30 ± 0.07 g) was
only 75 % of the MHCC-97 L/CTSB group (1.96 ±
0.06 g) (Fig. 7c). To correlate the biological response
with the mechanisms identified in cells, MMP-9 protein
was assessed by Western blot analysis. As shown in
Fig. 7e, MMP-9 expression was significantly increased in
five representative MHCC-97 L/CTSB tumors. In
Fig. 5 Effect of CTSB on HCC cell migration and invasion. a Effect of overexpression of CTSB on the cell migration of MHCC-97 L cells. As
detected by Wounding-healing assay. Migratory cells were quantified by counting three separate fields in different wells. The migratory
ability of MHCC-97 L/CTSB cells was remarkably increased compared to that of MHCC-97 L/Con and MHCC-97 L cells. b Effect of CTSB
down-regulation on the cell migration of MHCC-97H cells. MHCC-97H/CTSB-shRNA exhibited reduced cell motility compared with control. c Effect
of overexpression of CTSB on the invasive potential of MHCC-97 L cells. The number of cells that pass through Matrigel in MHCC-97 L/CTSB group
was higher than that in control groups. As detected by transwell assay. d Effect of CTSB down-regulation on the invasive potential of MHCC-97H
cells. The number of cells that pass through Matrigel in MHCC-97H/CTSB-shRNA group was lower than that in control groups. All the results were
represented as the mean ± SD from three independent experiments. (**P < 0.01 as compared to parental groups, *P < 0.05 as compared
to parental groups)
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addition, down-regulation of CTSB showed the opposite
effects (Fig. 7b, d, and f). The results indicate that CTSB
is able to promote HCC tumor growth in nude mice.
Discussion
The long-term survival of HCC patients remains unsat-
isfactory because of its high incidence of recurrence and
metastasis after hepatic resection. Thus, identification of
effective biomarkers for HCC patients is certainly a great
concern of medical researchers.
As an intense interest of current research, CTSB has
been proposed as a potentially effective biomarker for a
variety of cancers [20–25]. Many researchers concluded
that CTSB might be a metastasis-related gene, and con-
sequently in the clinic, it can serve as a predictor for
therapeutic outcome or prognosis of patients with can-
cers [26–34]. In this study, we found that 23.4 %
paraffin-embedded HCC cancer tissues showed strong
membrane and cytoplasm staining of CTSB, 40.2 %
HCC tissues showed moderate CTSB staining, and
36.4 % showed negative staining in tumor cells, while
the non-cancerous tissues presented mainly negative ex-
pression of CTSB, indicating that CTSB might play an
important role in the development and progression of
HCC. Furthermore, as determined by immunohisto-
chemistry, the incidence of CTSB protein expression in
poorly differentiated carcinomas was significantly
higher than that in well-differentiated tumors, sug-
gesting that high level of CTSB expression was re-
lated to poor tumor differentiation. Additionally, we
have shown that CTSB expression was correlated with
Fig. 6 CTSB regulates MMP-9 through PI3K/Akt signal pathway. a Stable expression of CTSB in MHCC-97 L increased the protein level of p-Akt
and MMP-9. b Down-regulation of CTSB in MHCC-97H decreased the protein level of p-Akt and MMP-9. c MMP-9 protein of MHCC-97H/CTSB-
shRNA cells stably transfected with pcDNA-MMP-9 increased most significant compared to MHCC-97H/CTSB-shRNA cells. d CTSB knockdown
cells stably transfected with MMP-9 showed increased invasive ability. e Treatment of MHCC-97 L/CTSB cells with LY294002, a PI3K inhibitor, led
to down-regulation of MMP-9 at protein levels. f MHCC-97 L/CTSB cells treated with LY294002 show decreased invasive ability. (**P < 0.01 as
compared to parental groups, *P < 0.05 as compared to parental groups)
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stage, recurrence, and tumor differentiation. There
was no significant correlation between CTSB expres-
sion and age, gender, Tumor size, Serum HBsAg,
Serum AFP, or liver cirrhosis. Our study suggests that
high level of CTSB expression might be positively
correlated with worse tumor biological features, such
as rapid tumor progression and metastases. Further-
more, by univariate analysis of the Cox proportional-
hazard model, CTSB expression, serum AFP, tumor
size, metastasis/recurrence, and TNM staging were
found to be associated with an increased risk of death
by HCC. Thus, CTSB might be a powerful prognostic
index of survival in HCC.
To confirm the findings above, we compared CTSB
expression in two HCC cell lines with different meta-
static potential. As shown in the results section, the cell
Fig. 7 Effect of CTSB on subcutaneous tumorigenicity of MHCC-97 L and MHCC-97H. a Tumor growth curve of after injection of nude mice with
CTSB or control vector expressing MHCC-97 L cells. b Tumor growth curve of nude mice injected by MHCC-97H cells transfected with CTSB-shRNA
or Con-shRNA. c MHCC-97 L/CTSB tumors showed a significant increase in tumor volume and weight compared with control tumors on day 21 after
injection. d MHCC-97H/CTSB-shRNA tumors showed a significant decrease in tumor volume and weight compared with control tumors on day 21 after
injection. e Western blot analysis of the expression of CTSB in MHCC-97 L/CTSB tumors and control tumors. f Western blot analysis of the
expression of CTSB in MHCC-97H/CTSB-shRNA tumors and control tumors
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line with high metastatic potential expressed more CTSB
mRNA and protein than did the cell line with low meta-
static potential. This also means that HCC cells with
higher metastatic potential contain more CTSB. CTSB is
considered to play various roles in regulating cellular
functions depending on specific cell type, substratum
and other factors. It has been shown to increase migra-
tion and invasion of fibroblast-like synoviocytes, to pro-
mote migration of glioma-initiating cells, and to induce
apoptosis of porcine oocyte. Although many studies have
been performed to determine the functional features of
CTSB in different tumors, little attention has been paid
to regulation of CTSB in HCC. To further testify the
role of CSTB in HCC, a series of relevant functional
experiments, from positive to negative, as well as from
in vitro to in vivo, were performed in our study.
A previous study indicated that the two cell lines
derived from the same host cell line, MHCC-97H and
MHCC-97 L, could provide an ideal cell model system
for the study of HCC metastasis and proliferation. To
understand the functions of CTSB, we established two
target cell lines: MHCC-97H silencing CTSB and
MHCC-97 L overexpressing CTSB. We observed an as-
sociation of up-regulation of CTSB with promotion of
cell migration and invasion in vitro, as well as an associ-
ation of knockdown of CTSB with the reverse. Addition-
ally, our study has also provided the first validation
about the oncogenic capacity of CTSB expression in
vivo. Up-regulation of CTSB in MHCC-97 L cells led to
an enhancement of tumorigenicity potential in mice,
while down-regulation of CTSB in MHCC-97H cells was
correlated with inhibition of tumoregenicity. All the re-
sults of the functional experiments are in agreement
with the findings derived from our clinical data. By dem-
onstrating the potential role of CTSB in HCC cell lines,
we hope that our study will provide a new insight into
CTSB in HCC progression.
Invasion is a characteristic feature of HCC and a major
poor prognostic factor in patients with HCC. Invasion of
malignant HCC requires degradation of the extracellular
matrix and the basement membrane. MMPs play an
important role in the proteolytic destruction of extracel-
lular matrix and basement membranes, they are there-
fore essential for tumor invasion [35]. MMP-9 has also
been implicated in HCC invasion and metastasis, and
upregulation of MMP-9 can be achieved by activation of
PI3K/Akt pathways [19]. In this study, we have shown
that CTSB is able to enhance PI3K/Aktoncogenic path-
ways in HCC cells. Therefore, CTSB may enhance cell
invasiveness by promoting MMP-9 expression both in
vitro and in vivo via PI3K/Akt pathways. Furthermore,
we also found that overexpression of stably transfected
MMP-9 partially rescued the invasiveness of CTSB
knockdown cells. In addition, previous study showed
that CTSB could enhance the activity of the matrix me-
talloproteinases (MMPs) by destroying their inhibitors
(e.g., TIMP1 and TIMP2) in human articular chondro-
cytes and maintain a high level of MMPs, thereby
promoting ECM degradation [36]. The above results
suggested that MMP-9 is a major downstream effector
of CTSB in regulating cell migration and invasion.
CTSB expression status, combined with clinicopath-
ological features and other biomarkers of HCC, may
be useful to stratify patients for individual treatment,
such as those of targeted therapy or chemotherapy.
Since the number of the cases in our study was not
too big, the relationship between CTSB expression
and metastases still requires to be evaluated. There-
fore, further studies are needed to clarify the mecha-
nisms by which CTSB is involved in the development
and progression of HCC.
Conclusions
In summary, CTSB was up-regulated in HCC. The ex-
pression level of CTSB was correlated with poor progno-
sis in patients with HCC. In addition, our study also
provides a better understanding in both the molecular
mechanism and functional role of CTSB in human
HCC. Our current work revealed that CTSB has an
oncogenic role in hepatocarcinogenesis by facilitating
cancer cell migration and invasion. Notably, CTSB can
up-regulate MMP-9 expression through PI3K/Akt sig-
naling in HCC. Our study indicated that CTSB was an
independent risk factor for poor prognosis and might be
a useful biomarker for therapeutic strategy and control
in HCC treatment.
Additional files
Additional file 1: Figure S1. Expression of CTSB in HCC cell lines.
(A) CTSB protein expression levels in MHCC-97H, MHCC-97 L, Huh-7,
HepG2, SMMC-7721, and Bel-7404 cell lines were determined by Western
blot. (B) CTSB Protein of Huh-7 cells stably transfected with pcDNA-CTSB
increased most significant compared to Huh-7/Con cells and Huh-7 cells.
(C) Effect of overexpression of CTSB on the invasive potential of Huh-7
cells. The number of cells that passed through Matrigel in Huh-7/CTSB
group was higher than that in control groups. (D) CTSB specific shRNA
resulted in the reduction of CTSB protein in Bel-7404 cells. (E) Effect of
CTSB down-regulation on the invasive potential of MHCC-97H cells. The
number of cells that passed through Matrigel in Bel-7404/CTSB-shRNA
group was lower than that in control groups. (**P < 0.01 as compared to
parental groups, *P < 0.05 as compared to parental groups). (TIF 538 kb)
Additional file 2: Figure S2. Effect of CTSB on the PI3K pathway. (A)
Down-regulation of CTSB decreased the protein levels of p-PI3K, p-Akt,
and p-mTOR. (B) Stable expression of CTSB increased the protein levels
of p-PI3K, p-Akt, and p-mTOR (TIF 408 kb)
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